Getting into the Brain: Potential of Nanotechnology in the Management of NeuroAIDS

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2016 Mar 6

PMID 26944096

Citations 68

Authors

Madhavan Nair

Rahul Dev Jayant

Ajeet Kaushik

Vidya Sagar

Affiliations

Soon will be listed here.

Abstract

In spite of significant advances in antiretroviral (ARV) therapy, the elimination of human immunodeficiency virus (HIV) reservoirs from the periphery and the central nervous system (CNS) remains a formidable task. The incapability of ARV to go across the blood-brain barrier (BBB) after systemic administration makes the brain one of the dominant HIV reservoirs. Thus, screening, monitoring, and elimination of HIV reservoirs from the brain remain a clinically daunting and key task. The practice and investigation of nanomedicine possesses potentials for therapeutics against neuroAIDS. This review highlights the advancements in nanoscience and nanotechnology to design and develop specific size therapeutic cargo for efficient navigation across BBB so as to recognize and eradicate HIV brain reservoirs. Different navigation and drug release strategies, their biocompatibility and efficacy with related challenges and future prospects are also discussed. This review would be an excellent platform to understand nano-enable multidisciplinary research to formulate efficient nanomedicine for the management of neuroAIDS.

Citing Articles

HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives.

Kelly S, Nightingale S, Gupta R, Collier D Trop Med Infect Dis. 2025; 10(2).

PMID: 39998049 PMC: 11860496. DOI: 10.3390/tropicalmed10020045.

Vitamin E nanoparticles enhance performance and immune status of Nile tilapia.

Farag E, Baromh M, El-Kalamwi N, Sherif A BMC Vet Res. 2024; 20(1):561.

PMID: 39668352 PMC: 11636036. DOI: 10.1186/s12917-024-04398-w.

Comparative efficacy of eugenol, eugenol nanoemulsion, and metronidazole against : An experimental study.

Khaki A, Youssefi M, Nasrabadi N Open Vet J. 2024; 14(10):2618-2627.

PMID: 39545181 PMC: 11560258. DOI: 10.5455/OVJ.2024.v14.i10.11.

Substance Addiction Rehabilitation Drugs.

Yuan S, Jiang S, Zhang Z, Li Z, Hu J Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794185 PMC: 11124501. DOI: 10.3390/ph17050615.

Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice.

Zhou L, Godse S, Sinha N, Kodidela S, Singh U, Kumar S Pharmaceutics. 2024; 16(4).

PMID: 38675216 PMC: 11054602. DOI: 10.3390/pharmaceutics16040555.

References

Saves M, Morlat P, Chene G, Peuchant E, Pellegrin I, Bonnet F . Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy. Clin Immunol. 2001; 99(3):347-52. DOI: 10.1006/clim.2001.5033. View

Megard I, Garrigues A, Orlowski S, Jorajuria S, Clayette P, Ezan E . A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res. 2002; 927(2):153-67. DOI: 10.1016/s0006-8993(01)03337-6. View

Holmes D, Morgan H . Single cell impedance cytometry for identification and counting of CD4 T-cells in human blood using impedance labels. Anal Chem. 2010; 82(4):1455-61. DOI: 10.1021/ac902568p. View

van der Sandt I, Gaillard P, Voorwinden H, De Boer A, Breimer D . P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm Res. 2001; 18(5):587-92. DOI: 10.1023/a:1011016923346. View

Burgess A, Shah K, Hough O, Hynynen K . Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 2015; 15(5):477-91. PMC: 4702264. DOI: 10.1586/14737175.2015.1028369. View

Kuo Y . Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int J Pharm. 2005; 290(1-2):161-72. DOI: 10.1016/j.ijpharm.2004.11.025. View

Dutta T, Garg M, Jain N . Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci. 2008; 34(2-3):181-9. DOI: 10.1016/j.ejps.2008.04.002. View

Kuo Y, Su F . Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm. 2007; 340(1-2):143-52. DOI: 10.1016/j.ijpharm.2007.03.012. View

Qin L, Gu Y, Zhang H, Xue Y . Bradykinin-induced blood-tumor barrier opening is mediated by tumor necrosis factor-alpha. Neurosci Lett. 2008; 450(2):172-5. DOI: 10.1016/j.neulet.2008.10.080. View

10.

Yang H . Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res. 2010; 27(9):1759-71. PMC: 2933363. DOI: 10.1007/s11095-010-0141-7. View

11.

Kabanov A, Alakhov V . Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst. 2002; 19(1):1-72. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i1.10. View

12.

Tanriverdi S, Chen L, Chen S . A rapid and automated sample-to-result HIV load test for near-patient application. J Infect Dis. 2010; 201 Suppl 1:S52-8. DOI: 10.1086/650387. View

13.

Ricardo-Dukelow M, Kadiu I, Rozek W, Schlautman J, Persidsky Y, Ciborowski P . HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol. 2007; 185(1-2):37-46. PMC: 2212599. DOI: 10.1016/j.jneuroim.2007.01.004. View

14.

Abbott N, Patabendige A, Dolman D, Yusof S, Begley D . Structure and function of the blood-brain barrier. Neurobiol Dis. 2009; 37(1):13-25. DOI: 10.1016/j.nbd.2009.07.030. View

15.

Liu H, Hua M, Yang H, Huang C, Chu P, Wu J . Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A. 2010; 107(34):15205-10. PMC: 2930577. DOI: 10.1073/pnas.1003388107. View

16.

Vyas T, Shahiwala A, Amiji M . Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm. 2007; 347(1-2):93-101. PMC: 2213794. DOI: 10.1016/j.ijpharm.2007.06.016. View

17.

Szebeni J, Wahl S, Betageri G, Wahl L, Gartner S, Popovic M . Inhibition of HIV-1 in monocyte/macrophage cultures by 2',3'-dideoxycytidine-5'-triphosphate, free and in liposomes. AIDS Res Hum Retroviruses. 1990; 6(5):691-702. DOI: 10.1089/aid.1990.6.691. View

18.

Harrigan P, Hogg R, Dong W, Yip B, Wynhoven B, Woodward J . Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005; 191(3):339-47. DOI: 10.1086/427192. View

19.

Gonzalez-Scarano F, Martin-Garcia J . The neuropathogenesis of AIDS. Nat Rev Immunol. 2005; 5(1):69-81. DOI: 10.1038/nri1527. View

20.

Wen X, Wang K, Zhao Z, Zhang Y, Sun T, Zhang F . Brain-targeted delivery of trans-activating transcriptor-conjugated magnetic PLGA/lipid nanoparticles. PLoS One. 2014; 9(9):e106652. PMC: 4154764. DOI: 10.1371/journal.pone.0106652. View